KAPUALabs - Nova (Page 20)

An exhaustive analysis of volume growth, international demand, and margin pressures shaping the metabolic health leader.

By KAPUALabs

/ 19 Aug 2026

Strong earnings and AI momentum may not protect Meta if discount rates rise, credit tightens, and infrastructure returns disappoint

By KAPUALabs

/ 19 Aug 2026

The bull case rests on ad dominance and AI optionality; the bear case lives in the capex-to-EBITDA ratio

By KAPUALabs

/ 19 Aug 2026

Bull case rests on a distribution moat and advertising upside; bear case flags $145 billion in capex with unproven returns

By KAPUALabs

/ 18 Aug 2026

A comprehensive analysis of how Meta is trading model exclusivity for ecosystem gravity, developer lock-in, and platform leverage.

By KAPUALabs

/ 18 Aug 2026

Distribution reach could compound for years, but unrecoverable weights may erode the pricing power Meta still needs.

By KAPUALabs

/ 18 Aug 2026

Mapping gigawatt-scale campuses, off-balance-sheet financing, and the path to third-party compute monetization

By KAPUALabs

/ 18 Aug 2026

Investors can see the spending, but the evidence that it pays off remains the market's central open question

By KAPUALabs

/ 18 Aug 2026

The New Mexico ruling reframes Section 230, transfers power from editorial to design, and rewrites the rules for every social platform

By KAPUALabs

/ 18 Aug 2026

An exhaustive examination of Mounjaro's global surge, Zepbound's monetization, and manufacturing capital allocation.

By KAPUALabs

/ 18 Aug 2026

Six straight beats ended with an EPS miss — the question is no longer whether Meta can grow, but how much is incremental.

By KAPUALabs

/ 18 Aug 2026

Vertical integration offers resilience, but rising rack densities, power bottlenecks, and overbuild risk cloud the returns outlook.

By KAPUALabs

/ 18 Aug 2026